Key figures

in CHF millions	2023	2022	2021	2020	2019
Net sales	624	725	497	445	525
Gross profit	260	294	161	190	227
Gross profit margin	41.7 %	40.6 %	32.3 %	42.8 %	43.2 %
EBITDA Chemistry	22	19	20	9	9
EBITDA Paper	37	81	‑ 8	17	55
EBITDA Packaging	43	31	12	28	24
EBITDA Other/Consolidation	-	-	2	-	-
EBITDA	102	131	26	55	88
EBITDA margin	16.3 %	18.1 %	5.2 %	12.4 %	16.8 %
Operating result EBIT	83	112	‑ 3 ¹	25	57
EBIT margin	13.3 %	15.5 %	‑ 0.5 %	5.5 %	10.8 %
Net result	79	101	‑ 151	47	48
Return on equity ROE	18.9 %	28.5 %	‑ 38.7 %	10.3 %	11.4 %
Cash flow ²	90	129	17	46	80
Cash flow from operating activities	110	98	16	55	61
Capital expenditures for fixed assets	35	34	25	19	23
Free cash flow	92	68	‑ 3	40	40
Total assets	598	666	560	704	703
Shareholders’ equity	436	400	310	472	441
Equity ratio	72.9 %	60.0 %	55.4 %	67.0 %	62.8 %
Net cash	107	45	‑ 15	‑ 2	‑ 30
Net debt to EBITDA ratio	n.a.	n.a.	0.6	0.0	0.3
Capital employed	325	344	319	468	477
Net operating profit after tax (NOPAT)	70	97	‑ 2	20	49
Return on capital employed (ROCE)	20.9 %	29.2 %	‑ 0.6 %	4.3 %	10.3 %
Headcount (FTE)	1 195	1 181	1 104	1 098	1 086

¹ before impairment

² before change in non-financial net working capital

in CHF	2023	2022	2021	2020	2019
Share price as at 31 December	85.00	78.00	61.00	72.60	79.20
Price-earnings ratio as at 31 December	6.5	4.6	‑ 2.4	9.3	9.8
Earnings per share	13.15	16.83	‑ 25.26	7.82	8.06
Dividend per share	4.00 ¹	4.50	1.30	1.80	1.80
Dividend yield	4.7 %	5.8 %	2.1 %	2.5 %	2.3 %
Market capitalization (in CHF millions)	510	468	366	436	475

¹ Board of Directors’ proposal to Annual General Meeting of 20 March 2024